CANNABIDIOL
Cannabidiol is a negative allosteric modulator of CB1 receptors.It is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC) in patients 1 year of age and older
oral; 100mg/ml Seizures Associated with Lennox-Gastaut Syndrome or Dravet Syndrome The recommended starting dosage is 2.5 mg/kg by mouth twice daily (5 mg/kg/day). After one week, the dosage can be increased to a maintenance dosage of 5 mg/kg twice daily (10 mg/kg/day). Based on individual clinical response and tolerability, CANNABIDIOL can be increased up to a maximum recommended maintenance dosage of 10 mg/kg twice daily (20 mg/kg/day). Seizures Associated with Tuberous Sclerosis Complex The recommended starting dosage is 2.5 mg/kg by mouth twice daily (5 mg/kg/day). Increase the dose weekly by 2.5 mg/kg twice daily (5 mg/kg/day), as tolerated, to a recommended maintenance dosage of 12.5 mg/kg twice daily (25 mg/kg/day).
-Pregnancy and Breastfeeding: Limited research exists on CBD's effects during pregnancy and breastfeeding, so caution is advised. -Interaction with Certain Medications: CBD may interact with medications metabolized by the liver's cytochrome P450 system, potentially affecting their efficacy. -Hypersensitivity.
Measure AST and ALT levels before starting Cannabidiol Paediatric: Safety and efficacy in pediatric patients below age of 1 year have not been established Pregnancy: Data not sufficient. Lactation: Data not sufficient Elderly: Use with caution
Diarrhea; transaminase elevations; decreased appetite; somnolence; pyrexia; and vomiting.
When cannabidiol and 1,2-benzodiazepine are combined, the likelihood or intensity of side effects may rise. When used in conjunction with abametapir, acalabrutinib, acenocoumarol, and abemaciclib, the serum concentration of cannabidiol can be raised. When coadministered with Abatacept, cannabidiol can have a faster rate of metabolism. Combining Abrocitinib with Cannabidiol may slow down its metabolism. Acebutolol's metabolism may be slowed down when coadministered with cannabidiol. When Cannabidiol is coadministered with Aceclofenac & Acemetacin, the risk or severity of hypertension may rise.
